From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi:10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Wasswa-Kintu S, Gan WQ, Man SF, Pare PD, Sin DD. Relationship between reduced forced expiratory volume in one second and the risk of lung cancer: a systematic review and meta-analysis. Thorax. 2005;60(7):570–575. doi:10.1136/thx.2004.037135
   PubMed Web of Science ®Google Scholar
• Skillrud DM, Offord KP, Miller RD. Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. Ann Intern Med. 1986;105(4):503–507. doi:10.7326/0003-4819-105-4-503
   PubMed Web of Science ®Google Scholar
• Huang R, Wei Y, Hung RJ, et al. Associated links among smoking, chronic obstructive pulmonary disease, and small cell lung cancer: a pooled analysis in the international lung cancer consortium. EBioMedicine. 2015;2(11):1677–1685. doi:10.1016/j.ebiom.2015.09.031
   PubMed Web of Science ®Google Scholar
• Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as predictors of lung cancer. Chest. 2018;153(6):1326–1335. doi:10.1016/j.chest.2018.01.049
   PubMed Web of Science ®Google Scholar
• de Torres JP, Marín JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease– incidence and predicting factors. Am J Respir Crit Care Med. 2011;184(8):913–919. doi:10.1164/rccm.201103-0430OC
   PubMed Web of Science ®Google Scholar
• Zhang R, Tan X, Chen Q, et al. 胸外科住院肺癌合并慢性阻塞性肺疾病的调查结果分析 [Investigation of lung cancer patients complicated with chronic obstructive pulmonary disease in thoracic surgical department]. Zhongguo Fei Ai Za Zhi. 2017;20(3):163–167. Chinese. doi:10.3779/j.issn.1009-3419.2017.03.04
   PubMedGoogle Scholar
• Barnes PJ. Endo-phenotyping of COPD patients. Expert Rev Respir Med. 2021;15(1):27–37. doi:10.1080/17476348.2020.1804364
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivée P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373. doi:10.1016/j.chest.2016.10.003
   PubMed Web of Science ®Google Scholar
• Ho J, He W, Chan MTV, et al. Eosinophilia and clinical outcome of chronic obstructive pulmonary disease: a meta-analysis. Sci Rep. 2017;7(1):13451. doi:10.1038/s41598-017-13745-x
   PubMed Web of Science ®Google Scholar
• Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. Am J Respir Crit Care Med. 2008;178(7):738–744. doi:10.1164/rccm.200803-435OC
   PubMed Web of Science ®Google Scholar
• Hohberger LA, Schroeder DR, Bartholmai BJ, et al. Correlation of regional emphysema and lung cancer: a lung tissue research consortium-based study. J Thorac Oncol. 2014;9(5):639–645. doi:10.1097/jto.0000000000000144
   PubMed Web of Science ®Google Scholar
• Bae K, Jeon KN, Lee SJ, et al. Severity of pulmonary emphysema and lung cancer: analysis using quantitative lobar emphysema scoring. Medicine. 2016;95(48):e5494. doi:10.1097/MD.0000000000005494
   PubMed Web of Science ®Google Scholar
• Tubío-Pérez RA, Torres-Durán M, Pérez-Ríos M, Fernández-Villar A, Ruano-Raviña A. Lung emphysema and lung cancer: what do we know about it? Ann Transl Med. 2020;8(21):1471. doi:10.21037/atm-20-1180
   PubMed Web of Science ®Google Scholar
• Mouronte-Roibás C, Fernández-Villar A, Ruano-Raviña A, et al. Influence of the type of emphysema in the relationship between COPD and lung cancer. Int J Chron Obstruct Pulmon Dis. 2018;13:3563–3570. doi:10.2147/copd.S178109
   PubMed Web of Science ®Google Scholar
• González J, Henschke CI, Yankelevitz DF, et al. Emphysema phenotypes and lung cancer risk. PLoS One. 2019;14(7):e0219187. doi:10.1371/journal.pone.0219187
   PubMed Web of Science ®Google Scholar
• Madan R, Matalon S, Vivero M. Spectrum of smoking-related lung diseases: imaging review and update. J Thorac Imaging. 2016;31(2):78–91. doi:10.1097/rti.0000000000000185
   PubMed Web of Science ®Google Scholar
• Chen AF, Davies CM, De Lin M, Fermor B. Oxidative DNA damage in osteoarthritic porcine articular cartilage. J Cell Physiol. 2008;217(3):828–833. doi:10.1002/jcp.21562
   PubMed Web of Science ®Google Scholar
• Donohue JF. Ageing, smoking and oxidative stress. Thorax. 2006;61(6):461–462. doi:10.1136/thx.2005.053058
   PubMed Web of Science ®Google Scholar
• Yarahmadi A, Zal F, Bolouki A. Protective effects of quercetin on nicotine induced oxidative stress in ‘HepG2 cells’. Toxicol Mech Methods. 2017;27(8):609–614. doi:10.1080/15376516.2017.1344338
   PubMed Web of Science ®Google Scholar
• Dialyna IA, Miyakis S, Georgatou N, Spandidos DA. Genetic polymorphisms of CYP1A1, GSTM1 and GSTT1 genes and lung cancer risk. Oncol Rep. 2003;10(6):1829–1835.
   PubMed Web of Science ®Google Scholar
• Ziolkowska-Suchanek I, Mosor M, Gabryel P, et al. Susceptibility loci in lung cancer and COPD: association of IREB2 and FAM13A with pulmonary diseases. Sci Rep. 2015;5:13502. doi:10.1038/srep13502
   PubMed Web of Science ®Google Scholar
• Ji X, Bosse Y, Landi MT, et al. Identification of susceptibility pathways for the role of chromosome 15q25.1 in modifying lung cancer risk. Nat Commun. 2018;9(1):3221. doi:10.1038/s41467-018-05074-y
   PubMed Web of Science ®Google Scholar
• Bjorngaard JH, Nordestgaard AT, Taylor AE, et al. Heavier smoking increases coffee consumption: findings from a Mendelian randomization analysis. Int J Epidemiol. 2017;46(6):1958–1967. doi:10.1093/ije/dyx147
   PubMed Web of Science ®Google Scholar
• Ji X, Gui J, Han Y, et al. The role of haplotype in 15q25.1 locus in lung cancer risk: results of scanning chromosome 15. Carcinogenesis. 2015;36(11):1275–1283. doi:10.1093/carcin/bgv118
   PubMed Web of Science ®Google Scholar
• Sundar IK, Mullapudi N, Yao H, Spivack SD, Rahman I. Lung cancer and its association with chronic obstructive pulmonary disease: update on nexus of epigenetics. Curr Opin Pulm Med. 2011;17(4):279–285. doi:10.1097/MCP.0b013e3283477533
   PubMed Web of Science ®Google Scholar
• Watza D, Lusk CM, Dyson G, et al. COPD-dependent effects of genetic variation in key inflammation pathway genes on lung cancer risk. Int J Cancer. 2020;147(3):747–756. doi:10.1002/ijc.32780
   PubMed Web of Science ®Google Scholar
• Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer. 2013;13(4):233–245. doi:10.1038/nrc3477
   PubMed Web of Science ®Google Scholar
• Parris BA, O’Farrell HE, Fong KM, Yang IA. Chronic obstructive pulmonary disease (COPD) and lung cancer: common pathways for pathogenesis. J Thorac Dis. 2019;11(Suppl 17):S2155–s2172. doi:10.21037/jtd.2019.10.54
   PubMed Web of Science ®Google Scholar
• Wauters E, Janssens W, Vansteenkiste J, et al. DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature. Thorax. 2015;70(12):1113–1122. doi:10.1136/thoraxjnl-2015-207288
   PubMed Web of Science ®Google Scholar
• Durham AL, Adcock IM. The relationship between COPD and lung cancer. Lung Cancer. 2015;90(2):121–127. doi:10.1016/j.lungcan.2015.08.017
   PubMed Web of Science ®Google Scholar
• Kapranov P, Cheng J, Dike S, et al. RNA maps reveal new RNA classes and a possible function for pervasive transcription. Science. 2007;316(5830):1484–1488. doi:10.1126/science.1138341
   PubMed Web of Science ®Google Scholar
• Devadoss D, Long C, Langley RJ, et al. Long noncoding transcriptome in chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol. 2019;61(6):678–688. doi:10.1165/rcmb.2019-0184TR
   PubMed Web of Science ®Google Scholar
• Jia M, Yao X. Epigenetic links to airway smooth muscle proliferation. Am J Respir Cell Mol Biol. 2019;61(5):552–553. doi:10.1165/rcmb.2019-0149ed
   PubMed Web of Science ®Google Scholar
• Greco S, Gaetano C, Martelli F. Long noncoding competing endogenous RNA networks in age-associated cardiovascular diseases. Int J Mol Sci. 2019;20(12):3079. doi:10.3390/ijms20123079
   PubMed Web of Science ®Google Scholar
• Gao S, Lin H, Yu W, et al. LncRNA LCPAT1 is involved in DNA damage induced by CSE. Biochem Biophys Res Commun. 2019;508(2):512–515. doi:10.1016/j.bbrc.2018.11.171
   PubMed Web of Science ®Google Scholar
• Mahmood MQ, Ward C, Muller HK, Sohal SS, Walters EH. Epithelial mesenchymal transition (EMT) and non-small cell lung cancer (NSCLC): a mutual association with airway disease. Med Oncol. 2017;34(3):45. doi:10.1007/s12032-017-0900-y
   PubMed Web of Science ®Google Scholar
• Huang RY, Wong MK, Tan TZ, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013;4(11):e915. doi:10.1038/cddis.2013.442
   PubMed Web of Science ®Google Scholar
• Jolly MK, Ward C, Eapen MS, et al. Epithelial-mesenchymal transition, a spectrum of states: role in lung development, homeostasis, and disease. Dev Dyn. 2018;247(3):346–358. doi:10.1002/dvdy.24541
   PubMed Web of Science ®Google Scholar
• Jolly MK, Boareto M, Huang B, et al. Implications of the hybrid epithelial/mesenchymal phenotype in metastasis. Front Oncol. 2015;5:155. doi:10.3389/fonc.2015.00155
   PubMed Web of Science ®Google Scholar
• Bocci F, Jolly MK, Tripathi SC, et al. Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. J R Soc Interface. 2017;14(136):20170512. doi:10.1098/rsif.2017.0512
   PubMed Web of Science ®Google Scholar
• Jolly MK, Boareto M, Debeb BG, et al. Inflammatory breast cancer: a model for investigating cluster-based dissemination. NPJ Breast Cancer. 2017;3:21. doi:10.1038/s41523-017-0023-9
   PubMed Web of Science ®Google Scholar
• Eapen MS, Myers S, Lu W, Tanghe C, Sharma P, Sohal SS. sE-cadherin and sVE-cadherin indicate active epithelial/endothelial to mesenchymal transition (EMT and EndoMT) in smokers and COPD: implications for new biomarkers and therapeutics. Biomarkers. 2018;23(7):709–711. doi:10.1080/1354750X.2018.1479772
   PubMed Web of Science ®Google Scholar
• Gurzu S, Turdean S, Kovecsi A, Contac AO, Jung I. Epithelial-mesenchymal, mesenchymal-epithelial, and endothelial-mesenchymal transitions in malignant tumors: an update. World J Clin Cases. 2015;3(5):393–404. doi:10.12998/wjcc.v3.i5.393
   PubMed Web of Science ®Google Scholar
• Ge F, Feng Y, Huo Z, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients: a comprehensive analysis of nine prospective cohorts. Transl Lung Cancer Res. 2021;10(3):1266–1276. doi:10.21037/tlcr-20-1126
   PubMed Web of Science ®Google Scholar
• Eapen MS, Hansbro PM, Larsson-Callerfelt AK, et al. Chronic obstructive pulmonary disease and lung cancer: underlying pathophysiology and new therapeutic modalities. Drugs. 2018;78(16):1717–1740. doi:10.1007/s40265-018-1001-8
   PubMed Web of Science ®Google Scholar
• Brody JS, Spira A. State of the art. Chronic obstructive pulmonary disease, inflammation, and lung cancer. Proc Am Thorac Soc. 2006;3(6):535–537. doi:10.1513/pats.200603-089MS
   PubMedGoogle Scholar
• Mei J, Xiao Z, Guo C, et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: a systemic review and meta-analysis. Oncotarget. 2016;7(23):34217–34228. doi:10.18632/oncotarget.9079
   PubMedGoogle Scholar
• Eapen MS, Hansbro PM, McAlinden K, et al. Abnormal M1/M2 macrophage phenotype profiles in the small airway wall and lumen in smokers and chronic obstructive pulmonary disease (COPD). Sci Rep. 2017;7(1):13392. doi:10.1038/s41598-017-13888-x
   PubMed Web of Science ®Google Scholar
• Almatroodi SA, McDonald CF, Darby IA, Pouniotis DS. Characterization of M1/M2 tumour-associated macrophages (TAMs) and Th1/Th2 cytokine profiles in patients with NSCLC. Cancer Microenviron. 2016;9(1):1–11. doi:10.1007/s12307-015-0174-x
   PubMed Web of Science ®Google Scholar
• Wang LE, Gorlova OY, Ying J, et al. Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. Cancer Res. 2013;73(1):256–264. doi:10.1158/0008-5472.Can-12-1915
   PubMed Web of Science ®Google Scholar
• Morlá M, Busquets X, Pons J, Sauleda J, MacNee W, Agustí AG. Telomere shortening in smokers with and without COPD. Eur Respir J. 2006;27(3):525–528. doi:10.1183/09031936.06.00087005
   PubMed Web of Science ®Google Scholar
• Ceylan E, Kocyigit A, Gencer M, Aksoy N, Selek S. Increased DNA damage in patients with chronic obstructive pulmonary disease who had once smoked or been exposed to biomass. Respir Med. 2006;100(7):1270–1276. doi:10.1016/j.rmed.2005.10.011
   PubMed Web of Science ®Google Scholar
• Schreck R, Albermann K, Baeuerle PA. Nuclear factor kappa B: an oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun. 1992;17(4):221–237. doi:10.3109/10715769209079515
   PubMed Web of Science ®Google Scholar
• Kirkham PA, Caramori G, Casolari P, et al. Oxidative stress-induced antibodies to carbonyl-modified protein correlate with severity of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;184(7):796–802. doi:10.1164/rccm.201010-1605OC
   PubMed Web of Science ®Google Scholar
• Osoata GO, Yamamura S, Ito M, et al. Nitration of distinct tyrosine residues causes inactivation of histone deacetylase 2. Biochem Biophys Res Commun. 2009;384(3):366–371. doi:10.1016/j.bbrc.2009.04.128
   PubMed Web of Science ®Google Scholar
• Whipple CA. Tumor talk: understanding the conversation between the tumor and its microenvironment. Cancer Cell Microenviron. 2015;2(2):e773. doi:10.14800/ccm.773
   PubMedGoogle Scholar
• Murakami J, Ueda K, Sano F, Hayashi M, Nishimoto A, Hamano K. Pulmonary emphysema and tumor microenvironment in primary lung cancer. J Surg Res. 2016;200(2):690–697. doi:10.1016/j.jss.2015.09.004
   PubMed Web of Science ®Google Scholar
• Mocchegiani E, Giacconi R, Costarelli L. Metalloproteases/anti-metalloproteases imbalance in chronic obstructive pulmonary disease: genetic factors and treatment implications. Curr Opin Pulm Med. 2011;17:S11–9. doi:10.1097/01.mcp.0000410743.98087.12
   PubMed Web of Science ®Google Scholar
• Hallgren O, Nihlberg K, Dahlbäck M, et al. Altered fibroblast proteoglycan production in COPD. Respir Res. 2010;11(1):55. doi:10.1186/1465-9921-11-55
   PubMed Web of Science ®Google Scholar
• Burgess JK, Mauad T, Tjin G, Karlsson JC, Westergren-Thorsson G. The extracellular matrix - the under-recognized element in lung disease? J Pathol. 2016;240(4):397–409. doi:10.1002/path.4808
   PubMed Web of Science ®Google Scholar
• Yang P, Sun Z, Krowka MJ, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. Arch Intern Med. 2008;168(10):1097–1103. doi:10.1001/archinte.168.10.1097
   PubMedGoogle Scholar
• Wu K, Xing F, Wu SY, Watabe K. Extracellular vesicles as emerging targets in cancer: recent development from bench to bedside. Biochim Biophys Acta Rev Cancer. 2017;1868(2):538–563. doi:10.1016/j.bbcan.2017.10.001
   PubMed Web of Science ®Google Scholar
• McCready J, Sims JD, Chan D, Jay DG. Secretion of extracellular hsp90alpha via exosomes increases cancer cell motility: a role for plasminogen activation. BMC Cancer. 2010;10:294. doi:10.1186/1471-2407-10-294
   PubMed Web of Science ®Google Scholar
• Zaravinos A. The regulatory role of MicroRNAs in EMT and cancer. J Oncol. 2015;2015:865816. doi:10.1155/2015/865816
   PubMed Web of Science ®Google Scholar
• Mongroo PS, Rustgi AK. The role of the miR-200 family in epithelial-mesenchymal transition. Cancer Biol Ther. 2010;10(3):219–222. doi:10.4161/cbt.10.3.12548
   PubMed Web of Science ®Google Scholar
• Silvestri GA, Young RP. Strange bedfellows: the interaction between COPD and lung cancer in the context of lung cancer screening. Ann Am Thorac Soc. 2020;17(7):810–812. doi:10.1513/AnnalsATS.202005-433ED
   PubMed Web of Science ®Google Scholar
• Park HY, Kang D, Shin SH, et al. Pulmonary tuberculosis and the incidence of lung cancer among patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2022;19(4):640–648. doi:10.1513/AnnalsATS.202010-1240OC
   PubMed Web of Science ®Google Scholar
• Young RP, Hopkins RJ. Chronic obstructive pulmonary disease (COPD) and lung cancer screening. Transl Lung Cancer Res. 2018;7(3):347–360. doi:10.21037/tlcr.2018.05.04
   PubMed Web of Science ®Google Scholar
• Detterbeck FC, Mazzone PJ, Naidich DP, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e78S–e92S. doi:10.1378/chest.12-2350
   PubMed Web of Science ®Google Scholar
• Wender R, Fontham ET, Barrera E, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin. 2013;63(2):107–117. doi:10.3322/caac.21172
   PubMed Web of Science ®Google Scholar
• Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg. 2012;144(1):33–38. doi:10.1016/j.jtcvs.2012.05.060
   PubMed Web of Science ®Google Scholar
• Wood DE, Kazerooni E, Baum SL, et al. Lung cancer screening, version 1.2015: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2015;13(1):23–34;quiz 34. doi:10.6004/jnccn.2015.0006
   PubMed Web of Science ®Google Scholar
• De-torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD lung cancer screening score. Am J Respir Crit Care Med. 2015;191(3):285–291. doi:10.1164/rccm.201407-1210OC
   PubMed Web of Science ®Google Scholar
• De-torres JP, Marín JM, Casanova C, et al. Identification of COPD patients at high risk for lung cancer mortality using the COPD-LUCSS-DLCO. Chest. 2016;149(4):936–942. doi:10.1378/chest.15-1868
   PubMed Web of Science ®Google Scholar
• Figueira Gonçalves JM, Pérez Mendez LI, Gurbani N, García-Talavera I, Pérez Pinilla JL. Applicability of the COPD-LUCSS-DLCO score for patients with chronic obstructive pulmonary disease: analysis in standard clinical practice conditions. Rev Clin Esp. 2018;218(7):336–341. Aplicabilidad del score COPD-LUCSS-DLCO en pacientes con enfermedad pulmonar obstructiva crónica: análisis en condiciones de práctica clínica habitual. doi:10.1016/j.rce.2018.04.008
   PubMed Web of Science ®Google Scholar
• Ji JJ, Fan J. Discovering myeloid cell heterogeneity in the lung by means of next generation sequencing. Mil Med Res. 2019;6(1):33. doi:10.1186/s40779-019-0222-9
   PubMed Web of Science ®Google Scholar
• Obeidat M, Nie Y, Fishbane N, et al. Integrative genomics of emphysema-associated genes reveals potential disease biomarkers. Am J Respir Cell Mol Biol. 2017;57(4):411–418. doi:10.1165/rcmb.2016-0284OC
   PubMed Web of Science ®Google Scholar
• Keller A, Fehlmann T, Ludwig N, et al. Genome-wide MicroRNA expression profiles in COPD: early predictors for cancer development. Genomics Proteomics Bioinformatics. 2018;16(3):162–171. doi:10.1016/j.gpb.2018.06.001
   PubMed Web of Science ®Google Scholar
• Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics. 2019;9(7):2056–2070. doi:10.7150/thno.28119
   PubMed Web of Science ®Google Scholar
• Su Z, Wang Z, Ni X, et al. Inferring the evolution and progression of small-cell lung cancer by single-cell sequencing of circulating tumor cells. Clin Cancer Res. 2019;25(16):5049–5060. doi:10.1158/1078-0432.Ccr-18-3571
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi:10.1038/nature22364
   PubMed Web of Science ®Google Scholar
• Hu J, Wang Y, Zhang Y, et al. Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential. Cancer Med. 2019;8(9):4338–4347. doi:10.1002/cam4.2199
   PubMed Web of Science ®Google Scholar
• Pavel AB, Campbell JD, Liu G, et al. Alterations in bronchial airway miRNA expression for lung cancer detection. Cancer Prev Res. 2017;10(11):651–659. doi:10.1158/1940-6207.Capr-17-0098
   PubMed Web of Science ®Google Scholar
• Licht JC, Grasemann H. Potential of the electronic nose for the detection of respiratory diseases with and without infection. Int J Mol Sci. 2020;21(24):9416. doi:10.3390/ijms21249416
   PubMed Web of Science ®Google Scholar
• Subramoniam M, Mathew L, Mathew L, et al. Noninvasive detection of COPD and lung cancer through breath analysis using MOS sensor array based e-nose. Expert Rev Mol Diagn. 2021;21(11):1223–1233. doi:10.1080/14737159.2021.1971079
   PubMed Web of Science ®Google Scholar
• Krauss E, Haberer J, Barreto G, Degen M, Seeger W, Guenther A. Recognition of breathprints of lung cancer and chronic obstructive pulmonary disease using the Aeonose((R)) electronic nose. J Breath Res. 2020;14(4):046004. doi:10.1088/1752-7163/ab8c50
   PubMed Web of Science ®Google Scholar
• López-Encuentra A, Astudillo J, Cerezal J, Gonzalez-Aragoneses F, Novoa N, Sánchez-Palencia A. Prognostic value of chronic obstructive pulmonary disease in 2994 cases of lung cancer. Eur J Cardiothorac Surg. 2005;27(1):8–13. doi:10.1016/j.ejcts.2004.09.010
   PubMed Web of Science ®Google Scholar
• Yi YS, Ban WH, Sohng KY. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. BMC Cancer. 2018;18(1):1053. doi:10.1186/s12885-018-4976-3
   PubMed Web of Science ®Google Scholar
• Mouronte-Roibás C, Leiro-Fernández V, Ruano-Raviña A, et al. Chronic obstructive pulmonary disease in lung cancer patients: prevalence, underdiagnosis, and clinical characterization. Respiration. 2018;95(6):414–421. doi:10.1159/000487243
   PubMed Web of Science ®Google Scholar
• Wang W, Dou S, Dong W, et al. Impact of COPD on prognosis of lung cancer: from a perspective on disease heterogeneity. Int J Chron Obstruct Pulmon Dis. 2018;13:3767–3776. doi:10.2147/COPD.S168048
   PubMed Web of Science ®Google Scholar
• Lim JU, Kang HS, Yeo CD, et al. Impact of combined chronic obstructive pulmonary disease status and systemic inflammation on outcome of advanced NSCLC: multicenter retrospective cohort study. Int J Chron Obstruct Pulmon Dis. 2020;15:3323–3334. doi:10.2147/copd.S274354
   PubMed Web of Science ®Google Scholar
• Dong W, Zhu Y, Du Y, Wang L, Feng X, Ma S. Impact of severe-to-very severe chronic obstructive pulmonary disease on the prognosis of patients with non-small cell lung cancer who received chemotherapy. Clin Respir J. 2020;14(4):345–352. doi:10.1111/crj.13139
   PubMed Web of Science ®Google Scholar
• Morimoto M, Nishino K, Wada K, et al. Elective nodal irradiation for non-small cell lung cancer complicated with chronic obstructive pulmonary disease affects immunotherapy αfter definitive chemoradiotherapy. Anticancer Res. 2020;40(12):6957–6970. doi:10.21873/anticanres.14720
   PubMed Web of Science ®Google Scholar
• Chun SG, Hu C, Choy H, et al. Impact of intensity-modulated radiation therapy technique for locally advanced non-small-cell lung cancer: a secondary analysis of the NRG oncology RTOG 0617 randomized clinical trial. J Clin Oncol. 2017;35(1):56–62. doi:10.1200/jco.2016.69.1378
   PubMed Web of Science ®Google Scholar
• Verma V, Shostrom VK, Zhen W, et al. Influence of fractionation scheme and tumor location on toxicities after stereotactic body radiation therapy for large (≥5 cm) non-small cell lung cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys. 2017;97(4):778–785. doi:10.1016/j.ijrobp.2016.11.049
   PubMed Web of Science ®Google Scholar
• Wang J, Cao J, Yuan S, et al. Poor baseline pulmonary function may not increase the risk of radiation-induced lung toxicity. Int J Radiat Oncol Biol Phys. 2013;85(3):798–804. doi:10.1016/j.ijrobp.2012.06.040
   PubMed Web of Science ®Google Scholar
• Henkenberens C, Janssen S, Lavae-Mokhtari M, et al. Inhalative steroids as an individual treatment in symptomatic lung cancer patients with radiation pneumonitis grade II after radiotherapy - a single-centre experience. Radiat Oncol. 2016;11:12. doi:10.1186/s13014-016-0580-3
   PubMed Web of Science ®Google Scholar
• McKendry RT, Spalluto CM, Burke H, et al. Dysregulation of antiviral function of CD8(+) T cells in the chronic obstructive pulmonary disease lung. Role of the PD-1-PD-L1 axis. Am J Respir Crit Care Med. 2016;193(6):642–651. doi:10.1164/rccm.201504-0782OC
   PubMed Web of Science ®Google Scholar
• Mark NM, Kargl J, Busch SE, et al. Chronic obstructive pulmonary disease alters immune cell composition and immune checkpoint inhibitor efficacy in non-small cell lung cancer. Am J Respir Crit Care Med. 2018;197(3):325–336. doi:10.1164/rccm.201704-0795OC
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Inui N, Karayama M, et al. Effect of PD-1 inhibitor on exhaled nitric oxide and pulmonary function in non-small cell lung cancer patients with and without COPD. Int J Chron Obstruct Pulmon Dis. 2019;14:1867–1877. doi:10.2147/copd.S214610
   PubMed Web of Science ®Google Scholar
• Dubinett SM, Spira AE. Impact of chronic obstructive pulmonary disease on immune-based treatment for lung cancer. Moving toward disease interception. Am J Respir Crit Care Med. 2018;197(3):278–280. doi:10.1164/rccm.201710-2065ED
   PubMed Web of Science ®Google Scholar
• Zhou J, Chao Y, Yao D, et al. Impact of chronic obstructive pulmonary disease on immune checkpoint inhibitor efficacy in advanced lung cancer and the potential prognostic factors. Transl Lung Cancer Res. 2021;10(5):2148–2162. doi:10.21037/tlcr-21-214
   PubMed Web of Science ®Google Scholar
• Shin SH, Park HY, Im Y, et al. Improved treatment outcome of pembrolizumab in patients with nonsmall cell lung cancer and chronic obstructive pulmonary disease. Int J Cancer. 2019;145(9):2433–2439. doi:10.1002/ijc.32235
   PubMed Web of Science ®Google Scholar
• Nair VS, Eaton K, McGarry Houghton A. A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients. Respir Med Case Rep. 2021;34:101541. doi:10.1016/j.rmcr.2021.101541
   PubMed Web of Science ®Google Scholar
• Biton J, Ouakrim H, Dechartres A, et al. Impaired tumor-infiltrating T cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. Am J Respir Crit Care Med. 2018;198(7):928–940. doi:10.1164/rccm.201706-1110OC
   PubMed Web of Science ®Google Scholar
• Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit smoking. Respir Med. 2009;103(1):85–90. doi:10.1016/j.rmed.2008.07.024
   PubMed Web of Science ®Google Scholar
• Wu MF, Jian ZH, Huang JY, et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD. BMC Cancer. 2016;16(1):778. doi:10.1186/s12885-016-2838-4
   PubMed Web of Science ®Google Scholar
• Makino T, Otsuka H, Hata Y, et al. Long-acting muscarinic antagonist and long-acting beta2-agonist therapy to optimize chronic obstructive pulmonary disease prior to lung cancer surgery. Mol Clin Oncol. 2018;8(5):647–652. doi:10.3892/mco.2018.1595
   PubMed Web of Science ®Google Scholar
• Bölükbas S, Eberlein M, Eckhoff J, Schirren J. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial. Eur J Cardiothorac Surg. 2011;39(6):995–1000. doi:10.1016/j.ejcts.2010.09.025
   PubMed Web of Science ®Google Scholar
• Kerksick C, Willoughby D. The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress. J Int Soc Sports Nutr. 2005;2(2):38–44. doi:10.1186/1550-2783-2-2-38
   PubMedGoogle Scholar
• Goebel C, Louden CL, McKenna R, Onugha O, Wachtel A, Long T. Blood test shows high accuracy in detecting stage I non-small cell lung cancer. BMC Cancer. 2020;20(1):137. doi:10.1186/s12885-020-6625-x
   PubMed Web of Science ®Google Scholar
• Batth IS, Mitra A, Manier S, et al. Circulating tumor markers: harmonizing the yin and yang of CTCs and ctDNA for precision medicine. Ann Oncol. 2017;28(3):468–477. doi:10.1093/annonc/mdw619
   PubMed Web of Science ®Google Scholar
• Pailler E, Faugeroux V, Oulhen M, et al. Acquired resistance mutations to ALK inhibitors identified by single circulating tumor cell sequencing in ALK-rearranged non-small-cell lung cancer. Clin Cancer Res. 2019;25(22):6671–6682. doi:10.1158/1078-0432.Ccr-19-1176
   PubMed Web of Science ®Google Scholar
• Pak S, Suh YS, Lee DE, et al. Association between postoperative detection of circulating tumor cells and recurrence in patients with prostate cancer. J Urol. 2020;203(6):1128–1134. doi:10.1097/JU.0000000000000704
   PubMed Web of Science ®Google Scholar
• Bayarri-Lara C, Ortega FG, Cueto Ladrón de Guevara A, et al. Circulating tumor cells identify early recurrence in patients with non-small cell lung cancer undergoing radical resection. PLoS One. 2016;11(2):e0148659. doi:10.1371/journal.pone.0148659
   PubMed Web of Science ®Google Scholar
• Hofman V, Ilie MI, Long E, et al. Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non-small-cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell method. Int J Cancer. 2011;129(7):1651–1660. doi:10.1002/ijc.25819
   PubMed Web of Science ®Google Scholar
• Lee CH, Hyun MK, Jang EJ, Lee NR, Kim K, Yim JJ. Inhaled corticosteroid use and risks of lung cancer and laryngeal cancer. Respir Med. 2013;107(8):1222–1233. doi:10.1016/j.rmed.2012.12.002
   PubMed Web of Science ®Google Scholar